A Trenton federal judge has dismissed a False Claims Act suit against Sanofi and Bristol-Myers Squibb over anti-blood clot drug Plavix, citing a change in the composition of the partnership that filed the suit.

The defendants in United States, ex rel. JKJ Partnership 2011 v. Sanofi Aventis U.S., filed in October 2011, are accused of failing to disclose that about 30 percent of the general public was genetically disposed to show diminished or no response to Plavix, including many African-Americans and Asian-Americans. The suit was filed by JKJ Partnership 2011, and became part of the consolidated litigation over Plavix, which is ongoing.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]